Ursodeoxycholic acid therapy for chronic type C hepatitis: A multicenter, dose-finding trial

Takikawa, Hajime; Yamanaka, Masami; Miyake, Kensuke; Kako, Makoto; Ohki, Hidenori; Narita, Tohru; Sugata, Fumio; Yoshiba, Makoto; Sekiyama, Kazuhiko; Aoyagi, Toshio; Nakajima, Hiroshi; Kamii, Kazuo; Matsumoto, Kazunori

doi:10.1016/s0011-393x(05)80073-6

Cited by 11 publications

(3 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As observed in a human study, 16 colestimide was shown to affect intestinal absorption of UDCA and the extent of the inhibition was similar to that by LCA, CDCA and DCA. Such results are similar to the report with cholestyramine 17 .…”

Section: Discussionsupporting

confidence: 71%

See 1 more Smart Citation

Effect of colestimide on absorption of unconjugated bile acids in the rat jejunum

Onishi¹,

Sano²,

Takikawa³

2002

J of Gastro and Hepatol

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 71%

“…Ursodeoxycholate (UDCA), the 7β‐epimer of chenodeoxycholate (CDCA), has been used for the treatment of cholesterol gallstones, 11,12 primary biliary cirrhosis 13,14 and chronic hepatitis 15,16 . There may be an interaction in cholestatic patients undergoing treatment with UDCA, as has been observed with cholestyramine 17 .…”

Section: Introductionmentioning

confidence: 99%

Effect of colestimide on absorption of unconjugated bile acids in the rat jejunum

Onishi¹,

Sano²,

Takikawa³

2002

J of Gastro and Hepatol

Self Cite

View full text Add to dashboard Cite

show abstract

“…Frequently, patients with cholestasis, such as drug‐induced cholestasis, obstructive jaundice and primary biliary cirrhosis (PBC), suffer from severe itching. Ursodeoxycholic acid (UDCA), the 7β‐epimer of chenodeoxycholic acid (CDCA), has been shown to be beneficial for the treatment of cholesterol gallstones, 2 chronic hepatitis, 3,4 and PBC 5–7 . Some researchers have previously reported the long‐term administration of UDCA to be a safe and effective treatment for the improvement of both biliary enzyme levels and pruritus in PBC 5,6 .…”

Section: Introductionmentioning

confidence: 99%

Colestimide: The efficacy of a novel anion‐exchange resin in cholestatic disorders

Matsuzaki

2002

J of Gastro and Hepatol

View full text Add to dashboard Cite

Interferon and ursodeoxycholic acid combined therapy in the treatmet of chronic viral C hepatitis: Results from a controlled randomized trial in 80 patients

et al. 1995

View full text Add to dashboard Cite

Because 70% to 75% of patients with chronic hepatitis C either do not respond to or relapse after interferon (IFN) therapy, and because ursodeoxycholic acid (UDCA) has been shown to reduce aminotransferase levels in patients with chronic hepatitis, we undertook a prospective controlled randomized trial of IFN (group I) versus IFN plus UDCA (group II) in 80 patients with chronic hepatitis C. IFN was administered in both groups for 6 months (3 to 5 million units [MU] three times a week), and in group II UDCA (10 mg/kg/d) was administered with IFN and then alone for 3 additional months. Response to therapy was defined as the normalization of alanine transaminase (ALT) levels. The results showed that 6 months after cessation of IFN, 59% of responders had relapsed in group I but only 27% had relapsed in group II (P = .03). There was no difference between the two groups for the initial (month 6) and the late (months 15 and 18) response rates to IFN. There was no virological effect or significant histological improvement attributable to the addition of UDCA to IFN treatment. In conclusion, the results of this study show that the addition of UDCA to IFN therapy significantly prolongs the period for which serum ALT remain, within the normal range after discontinuation of IFN. Further studies would be required to determine whether UDCA has any potential for long-term amelioration of the histological severity of liver disease caused by hepatitis C virus (HCV) infection, and, therefore, whether it could be advocated as an adjunct to antiviral therapy.

show abstract

Ursodeoxycholic acid therapy for chronic type C hepatitis: A multicenter, dose-finding trial

Cited by 11 publications

References 13 publications

Effect of colestimide on absorption of unconjugated bile acids in the rat jejunum

Effect of colestimide on absorption of unconjugated bile acids in the rat jejunum

Colestimide: The efficacy of a novel anion‐exchange resin in cholestatic disorders

Interferon and ursodeoxycholic acid combined therapy in the treatmet of chronic viral C hepatitis: Results from a controlled randomized trial in 80 patients

Contact Info

Product

Resources

About